Sign in

CIK 0002012593

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Rapport Therapeutics, Inc.

Sign in to watch
Ticker
RAPP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
880724208
Phone
+1 857-321-8020
Business address
99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
Former names
Rapport Therapeutics, Inc.
Open-market buys, last 90 days
$22,023,904
in 7 filings
Open-market sales, last 90 days
$4,470,180
in 7 filings, $4.5M under 10b5-1 plans

Net +$17,553,724. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-09-17 Ceesay Abraham Chief Executive Officer Sale 10b5-1 −34,885 $26.30 $918K 46,844
2025-09-17 Ceesay Abraham Chief Executive Officer Sale 10b5-1 −700 $27.04 $19K 46,144
2025-09-15 Bredt David Chief Scientific Officer Sale 10b5-1 −5,098 $23.88 $122K 421,544
2025-09-15 Bredt David Chief Scientific Officer Sale 10b5-1 −3,402 $24.66 $84K 418,142
2025-09-08 Gault Cheryl Chief Operating Officer Sale 10b5-1 −5,000 $38.33 $192K 171,928
2025-08-15 Bredt David Chief Scientific Officer Sale 10b5-1 −8,300 $14.98 $124K 426,842
2025-08-15 Bredt David Chief Scientific Officer Sale 10b5-1 −200 $15.79 $3K 426,642
2025-07-15 Bredt David Chief Scientific Officer Sale 10b5-1 −8,500 $14.00 $119K 435,142
2025-06-16 Bredt David Chief Scientific Officer Sale 10b5-1 −8,500 $11.00 $94K 443,642
2025-05-15 Bredt David Chief Scientific Officer Sale 10b5-1 −8,500 $9.56 $81K 452,142
2025-04-15 Bredt David Chief Scientific Officer Sale 10b5-1 −8,500 $9.57 $81K 460,642
2025-03-14 Bredt David Chief Scientific Officer Sale 10b5-1 −8,500 $10.85 $92K 469,142

Page 5 of 5 · 92 trades